Report in English with a Dutch summary (KCE reports 45A)

226 Screening for Colorectal Cancer KCE reports vol.45
159. Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, et al.
HNPCC-associated small bowel cancer: clinical and molecular characteristics.
Gastroenterology. 2005;128(3):590-9.
160. Velayos FS, Allen BA, Conrad PG, Gum J, Jr., Kakar S, Chung DC, et al. Low rate of
microsatellite instability in young patients with adenomas: reassessing the Bethesda
guidelines. American Journal of Gastroenterology. 2005;100(5):1143-9.
161. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst.
1999;91(11):916-32.
162. Huang SC, Lavine JE, Boland PS, Newbury RO, Kolodner R, Pham TT, et al.
Germline characterization of early-aged onset of hereditary non-polyposis colorectal
cancer. Journal of Pediatrics. 2001;138(5):629-35.
163. Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, et al.
Antibody-based screening for hereditary nonpolyposis colorectal carcinoma
compared with microsatellite analysis and sequencing. Cancer. 2002;95(11):2422-30.
164. Jo W-S, Chung DC. Genetics of hereditary colorectal cancer. Seminars in Oncology.
2005;32(1):11-23.
165. Marroni F, Pastrello C, Benatti P, Torrini M, Barana D, Cordisco EL, et al. A genetic
model for determining MSH2 and MLH1 carrier probabilities based on family history
and tumor microsatellite instability. Clinical Genetics. 2006;69(3):254-62.
166. Stormorken AT, Hoff G, Norstein J, Bowitz-Lothe IM, Hanslien E, Grindedal E, et al.
Estimated prevalence of hereditary cancers and the need for surveillance in a
Norwegian county, Telemark. Scand J Gastroenterol. 2006;41(1):71-9.
167. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the
prevalence of family history of cancer: implications for cancer screening and
prevention. Genetics in Medicine. 2006;8(9):571-5.
168. Mitchell RJ, Campbell H, Farrington SM, Brewster DH, Porteous MEM, Dunlop MG.
Prevalence of family history of colorectal cancer in the general population. British
Journal of Surgery. 2005;92(9):1161-4.
169. Field MJL, K.N.,. Guidelines for clinical practice. From development to use.
Washington D.C.: National academy press; 1992.
170. University of Oxford. Centre for Evidence-Based Medicine. http://www.cebm.net/.
2006.
171. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al.
Consensus development methods, and their use in clinical guideline development.
Health Technology Assessment (Winchester, England). 1998;2(3):i-iv.
172. Lohr KN, Carey TS. Assessing "best evidence": issues in grading the quality of studies
for systematic reviews. Joint Commission Journal on Quality Improvement.
1999;25(9):470-9.
173. AHRQ. Publication No. 02-E015: Systems to Rate the Strength of Scientific Evidence.
2002.
174. AGREE collaboration. Appraisal of Guidelines Research and Evaluation (AGREE)
Instrument. 2001.
175. NICE. The guideline development process - an overview for stakeholders, the public
and the NHS (second edition). 2006.
176. SIGN. SIGN 50: A guideline developers' handbook. 2001;Publication No.50.
177. NICE. The guidelines manual 2006. 2006.
178. Woolf SH. Practice guidelines, a new reality in medicine. II. Methods of developing
guidelines. Archives of Internal Medicine. 1992;152(5):946-52.
179. ACCP. Recommendations on cancer screening in the European union. Advisory
Committee on Cancer Prevention. Eur J Cancer. 2000;36(12):1473-8.
180. ICSI. Colorectal Cancer Screening.
http://www.icsi.org/display_file.asp?FileId=148&title=Colorectal%20Cancer%20Scree
ning. 2006.